Dehydroepiandrosterone (DHEA) modulates neurogenesis, neuronal function, neuronal survival and metabolism, enhancing mitochondrial oxidative capacity. Glucose deprivation and hypometabolism have been implicated in the mechanisms that mediate neuronal damage in neurological disorders, and some studies have shown that these mechanisms are sexually dimorphic. It was also demonstrated that DHEA is able to attenuate the hypometabolism that is related to some neurodegenerative diseases, eliciting neuroprotective effects in different experimental models of neurodegeneration. The aim of this study was to evaluate the effect of DHEA on the viability of male and female hippocampal neurons and SH-SY5Y neuroblastoma cells exposed to glucose deprivation. It was observed that after 12 h of pre-treatment, DHEA was able to protect SH-SY5Y cells from glucose deprivation for 6 h (DHEA 10 À 12 , 10 À 8 and 10 À 6 M) and 8 h (DHEA 10 À 8 M). In contrast, DHEA was not neuroprotective against glucose deprivation for 12 or 24 h. DHEA (10 À 8 M) also protected SH-SY5Y cells when added together or even 1 h after the beginning of glucose deprivation (6 h). Furthermore, DHEA (10 À 8 M) also protected primary neurons from both sexes against glucose deprivation. In summary, our findings indicate that DHEA is neuroprotective against glucose deprivation in human neuroblastoma cells and in male and female mouse hippocampal neurons. These results suggest that DHEA could be a promising candidate to be used in clinical studies aiming to reduce neuronal damage in people from both sexes.
a b s t r a c t
Dehydroepiandrosterone (DHEA) modulates neurogenesis, neuronal function, neuronal survival and metabolism, enhancing mitochondrial oxidative capacity. Glucose deprivation and hypometabolism have been implicated in the mechanisms that mediate neuronal damage in neurological disorders, and some studies have shown that these mechanisms are sexually dimorphic. It was also demonstrated that DHEA is able to attenuate the hypometabolism that is related to some neurodegenerative diseases, eliciting neuroprotective effects in different experimental models of neurodegeneration. The aim of this study was to evaluate the effect of DHEA on the viability of male and female hippocampal neurons and SH-SY5Y neuroblastoma cells exposed to glucose deprivation. It was observed that after 12 h of pre-treatment, DHEA was able to protect SH-SY5Y cells from glucose deprivation for 6 h (DHEA 10 À 12 , 10 À 8 and 10 À 6 M) and 8 h (DHEA 10 À 8 M). In contrast, DHEA was not neuroprotective against glucose deprivation for 12 or 24 h. DHEA (10 À 8 M) also protected SH-SY5Y cells when added together or even 1 h after the beginning of glucose deprivation (6 h). Furthermore, DHEA (10 À 8 M) also protected primary neurons from both sexes against glucose deprivation. In summary, our findings indicate that DHEA is neuroprotective against glucose deprivation in human neuroblastoma cells and in male and female mouse hippocampal neurons. These results suggest that DHEA could be a promising candidate to be used in clinical studies aiming to reduce neuronal damage in people from both sexes. & 2016 Elsevier B.V. All rights reserved.
Introduction
Steroid hormones are molecules mainly produced by endocrine glands, such as the adrenal glands, gonads and placenta, which are involved in the control of many physiological processes. In 1981, it was demonstrated that some steroids could be also produced by the nervous system, and the term "neurosteroids" was introduced to denominate the steroids that are synthetized in the nervous system independently of peripheral endocrine glands (Corpechot et al., 1981) . Dehydroepiandrosterone (DHEA) was the first neurosteroid identified and is one of the most abundant circulating hormones in humans (Charalampopoulos et al., 2008a (Charalampopoulos et al., , 2008b Corpechot et al., 1981) . In addition to be classified as a neurosteroid, DHEA is also called neuroactive steroid, due to its modulatory actions on the central nervous system (CNS) .
The physiological actions of DHEA involve both genomic and non-genomic mechanisms, including the activation of androgen/ estrogen receptors and the allosteric modulation of multiple receptors . Previous studies revealed that DHEA modulates neurogenesis, neuronal function, neuronal survival and metabolism, enhancing mitochondrial oxidative capacity (Corpechot et al., 1981) . DHEA and its sulfate ester (DHEAS) have been shown to attenuate excitotoxicity, protecting neuronal cells against excitatory amino acids and glucocorticoid toxicity (Kimonides et al., 1999; Kurata et al., 2004; Xilouri and Papazafiri, 2008) . In addition, DHEA protects glial/neuronal mixed hippocampal cultures and human neuroblastoma cells against oxidative stressinduced damage (Bastianetto et al., 1999; Gao et al., 2005) and antagonizes the neurotoxic effects of corticosterone in primary cultures of hippocampal neurons (Kimonides et al., 1999) . Moreover, DHEA and DHEAS protect against cell death induced by anoxia in rat embryonic cerebral cortical cultures (Marx et al., 2000) . Furthermore, DHEA and DHEAS protect retinoic acid-differentiated SH-SY5Y cells from death induced by both staurosporine (a nonspecific protein kinase inhibitor that is widely used for inducing mitochondrial apoptotic cell death) and doxorubicin (an activator of the death receptor signaling pathway) (Leoekiewicz et al., 2008) . In vivo, DHEA and DHEAS are also neuroprotective against brain ischemia (Li et al., 2009 ). Additionally to its neuroprotective effects on brain ischemia in vivo, DHEA is also neuroprotective in neurotrophin-deprivation conditions (Lazaridis et al., 2011) . The brain is a highly oxidative organ that depends on a continuous glucose supply due to its limited capacity of energy stores (Dienel and Cruz, 2004) . Glucose is essential to brain homeostasis and development (Lucas et al., 1988) and an inadequate glucose supply causes neuronal damage and increases the risk of neuropsychological dysfunctions (Almeida et al., 2002) . Glucose deprivation, decreased blood supply and glucose hypometabolism have been also implicated in the neuronal death after brain ischemia and in Alzheimer's (AD) and Parkinson's disease (PD) (Albrecht et al., 2005; Baquer et al., 2009; Woo et al., 2010) .
Hypometabolism in different regions of the brain, occurring as a consequence of multiple metabolic defects, is an early feature of AD (Moreira et al., 2009; Mosconi et al., 2008) . Senile demented AD patients have reduced cerebral metabolic rate for glucose compared to elderly normal subjects and this decrease in glucose metabolism is correlated with cognitive performance, suggesting its use as a marker of disease progression (de Leon et al., 1983) . AD patients present a reduced cerebral glucose transport activity (Kalaria et al., 1988) , decreased levels of glucose transporters (GLUT1 and GLUT3) (Liu et al., 2008) and decreased glycolytic activity in their brains (Bigl et al., 2003) . DHEA modulates metabolism, and the increase of glucose uptake can ameliorate brain metabolism of AD patients (Fuller et al., 2007) . DHEA levels decrease with age and altered DHEA levels have been related to AD and dementia in humans (Genazzani et al., 2007; Weill-ENGerer et al., 2002) . Previous work by our group showed an interaction between lactate and DHEA on the regulation of glucose uptake in different brain structures in vitro (De Souza et al., 2012) . While DHEA had no significant effect on glucose uptake in the cerebellum, hippocampus or hypothalamus, it increased glucose uptake in the cerebral cortex in the presence of lactate and in the olfactory bulb in the absence of lactate, suggesting that DHEA may enhance glucose uptake in specific conditions (De Souza et al., 2012) .
There are significant sex differences in the pathophysiology, epidemiology and clinical manifestations of many neurological diseases. Studies show that men are more susceptible to PD than women (Wooten et al., 2004) and present a higher mortality after stroke when affected before elderly (Reeves et al., 2008) , possibly due to the lack neuroprotection provided by female steroids such as estrogen and progesterone. These observations are supported by studies showing that there are sex differences in the mechanisms that mediate neuronal death in different experimental models (Du et al., 2004; Lieb et al., 1995; Renolleau et al., 2008) . Interestingly, it is known that male and female animals show different levels of neuroactive steroids, such as progesterone (PROG), tetrahydroprogesterone (THP), testosterone (T), dihydrotestosterone (DHT), DHEA and 3α-androstenediol (3α-diol) in some brain structures (Pesaresi et al., 2010) , and this may contribute to the differences observed in the regulation of neuronal survival between both sexes. Nevertheless, up to date, few studies were performed to identify the effect of neuroactive steroids in the neuronal survival of cultures from different sexes. Therefore, the aim of this study was to evaluate the effect of DHEA on the viability of male and female hippocampal neurons and SH-SY5Y neuroblastoma cells exposed to glucose deprivation.
Results

Glucose deprivation reduced SH-SY5Y cell viability
In order to select a time of glucose deprivation that was able to induce cell death, we performed a time-viability curve. We analyzed the effect of 6, 8, 12 and 24 h of glucose deprivation in the viability of SH-SY5Y cells. Glucose deprivation reduced SH-SY5Y cell viability in all the times tested (Fig. 1). 
DHEA protect SH-SY5Y cells from glucose deprivation
To determinate the optimal time and dose for DHEA treatment, cells were pretreated for 12 h with three doses of the hormone (10 À 12 , 10 À 8 or 10 À 6 M) and exposed to glucose deprivation for 6, 8, 12 and 24 h. DHEA was able to protect the cells from glucose deprivation for 6 h (DHEA 10 À 12 , 10 À 8 and 10 À 6 M) ( Fig. 2(a) and (b)) and 8 h (DHEA 10 À 8 M) (Fig. 2(c) and (d)). DHEA did not protect the cells against 12 h of glucose deprivation ( Fig. 2 (e) and (f)) or 24 h (Fig. 2(g ) and (h)).
2.3. DHEA protects SH-SY5Y cells from glucose deprivation without pre-treatment DHEA (10 À 8 M) was able to protect SH-SY5Y cells from glucose deprivation for 6 h when the hormone was added at the beginning of glucose deprivation (i.e., no pre-treatment period) (Fig. 3) or when the hormone was added one hour after the beginning of glucose deprivation (Fig. 4) .
DHEA protects male and female hippocampal neuronal cultures from glucose deprivation
After the identification of the neuroprotective effects of DHEA against glucose deprivation in SH-SY5Y cells, we analyzed the effect of DHEA (10 À 8 M) on the viability of male and female hippocampal neurons exposed to glucose deprivation for 6 h. We marked the nuclei of neurons with DAPI (blue), axons with antiTau (red) and dendrites with anti-MAP2 (green). The merge was made by superimposing the images. The pre-treatment with DHEA was able to protect both male ( Fig. 5(a) and (b)) and female ( Fig. 5 (c) and (d)) hippocampal neuronal cultures against glucose deprivation.
Discussion
This study reveals that DHEA is neuroprotective against glucose deprivation in male and female hippocampal neurons and in human neuroblastoma cells. The results presented here are consistent with several in vitro and in vivo studies demonstrating that DHEA has neuroprotective effects in different experimental models of neurodegenerative diseases (Bastianetto et al., 1999; Gao et DHEA (10 À 6 and 10 À 8 M) and DHEAS (10 À 6 M) protect against cell death induced by anoxia in rat embryonic cerebral cortical cultures (Marx et al., 2000) . DHEA (0.1 mM and 1 mM) and DHEAS (0.1 mM and 1 mM) were protective in retinoic acid-differentiated SH-SY5Y cells from death induced by both staurosporine (a nonspecific protein kinase inhibitor that is widely used for inducing mitochondrial apoptotic cell death) and doxorubicin (an activator of the death receptor signaling pathway) (Leoekiewicz et al., 2008) . When used in doses between 10 and 100 mM, DHEA exhibited antioxidant effects in models of oxidative stress using rat primary hippocampal cells and human hippocampal tissue from AD patients and age-matched controls (Bastianetto et al., 1999) . DHEA also protects human neuroblastoma cells against oxidative stress-induced damage in doses between 10 and 100 nM (Gao et al., 2005) . Furthermore, DHEA (100 nM) antagonizes the neurotoxic effects of corticosterone in primary cultures of hippocampal neurons (Kimonides et al., 1999) . Several mechanisms of action have been proposed to mediate the neuroprotective actions of DHEA in different experimental models and could be also related to its neuroprotective effects against glucose deprivation. DHEA is able to activate different signaling pathways related to the regulation of cell survival, including PI3K/Akt (Janner et al., 2010) and MEK/ERK (Charalampopoulos et al., 2006) pathways and enhances NF-kappaBdependent transcription factor activity (Mao and Barger, 1998) , increasing the expression of the anti-apoptotic protein Bcl-2 (Aly et al., 2011; Charalampopoulos et al., 2004) and decreasing the expression of the pro-apoptotic protein Bad (Charalampopoulos et al., 2008a (Charalampopoulos et al., , 2008b . In addition to the actions directly mediated by DHEA, some studies have also hypothesized that the neuroprotective effects of the hormone may be mediated by its conversion into estradiol (Aragno et al., 1997; Hoyk et al., 2004) , which has been shown to be neuroprotective against a variety of insults (Arevalo et al., 2015) , including glucose deprivation (Hernández-Fonseca et al., 2012) . Male and female neurons are differently affected by several insults, such as ischemia, OGD and glutamate excitotoxicity (Fairbanks et al., 2012; Li et al., 2005; Mohagheghi et al., 2013; Sharma et al., 2010; Zuo et al., 2013) . Regarding this aspect, DHEA exerted similar neuroprotective actions in male and female hippocampal neurons. In contrast to other neuroprotective hormones, such as estradiol, sex does not seem to be a limitation for the use of DHEA as a neuroprotective agent, suggesting that DHEA may be used as a therapeutic agent in both men and women.
Our findings indicate that DHEA is able to protect neuroblastoma cells when glucose deprivation is prolonged up to 8 h. However, DHEA was unable to protect the cells when glucose deprivation was prolonged for 12 h or more. This limit in the protective action of DHEA may be due to the progressive deterioration of mitochondrial function along glucose deprivation (Liu et al., 2003) . The protection of mitochondrial function is one of the possible mechanisms involved in the neuroprotective effects of DHEA in glucose deprived neurons (Morin et al., 2002; Grimm et al., 2014; Patel and Katyare, 2006) . However, DHEA may be unable to elicit these effects when mitochondrial dysfunction is excessive.
An important observation is that preincubation of neuroblastoma cells with DHEA before glucose deprivation was not necessary for its neuroprotective action, as DHEA was protective even when added one hour after the initiation of glucose deprivation. This finding suggests that there is a window of opportunity for the use of DHEA as a neuroprotectant after a neuronal insult.
Conclusions
In summary, our findings indicate that DHEA is neuroprotective against glucose deprivation in human neuroblastoma cells and in male and female mouse hippocampal neurons. Furthermore, DHEA exerts neuroprotective actions when administered even one hour after neuronal injury. These results suggest that DHEA is a promising candidate to be used in clinical studies aiming to reduce neuronal damage in both sexes. 
SH-SY5Y neuroblastoma cell cultures
SH-SY5Y human female neuroblastoma cells purchased from American Type Culture Collection (Manassas, VA) were cultured in DMEM-F12 supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin/ streptomycin. The cells were cultured in flasks and were kept in a humidified incubator containing 5% CO 2 in air at 37°C. The medium were changed every 2-3 days. Cells were passaged twice per week and were not used after 10 passages. The cells were seeded in 48-well plates and differentiated with 10 μM retinoic acid for 6 days, and fresh medium containing retinoic acid was changed every 48 h. For drug treatments, cells were starved of serum for 12 h using serum-free medium.
SH-SY5Y neuroblastoma cell treatments
Cells were pre-treated for 12 h with fresh serum-free medium containing vehicle (DMSO 0.1%) or DHEA (10 À 12 , 10 À 8 or 10 À 6 M).
After pre-treatments, cells were treated for different times (6 h, 8 h, 12 h and 24 h) with serum-free medium containing no glucose (glucose free DMEM) and vehicle (0.1% DMSO) or DHEA (10 À 12 , 10 À 8 or 10 À 6 M).
Cell Viability Assay in SH-SY5Y neuroblastoma cells
To assess cell viability, we performed the fluorescein diacetate (FDA)/propidium iodide (PI) assay. After treatments, cells were incubated for 50 min at 37°C with 100 μM FDA and 15 μM PI. The plates were read in a fluorimeter (Fluostar Optima; BMG Labtechnologies, Offenburg, Germany) and cell viability was determined using the ratio of the fluorescence emitted by alive/dead cells Â 100 (values are expressed as % of control).
Animals
CD1 mice were raised in the Cajal Institute, CSIC Madrid-Spain, and used to generate embryos for this study. The day of vaginal plug was defined as E0. All procedures for handling and killing the animals used in this study were in accordance with the European Commission guidelines (86/609/CEE and 2010/63/UE) and were approved by the institutional animal care and use committee.
Primary cultures of hippocampal neurons
The hippocampus was dissected out from male and female embryonic day 17 mouse embryos and dissociated to single cells after digestion with trypsin and DNase I (Goslin and Banker, 1989) . The hippocampal neurons were plated on glass coverslips coated with poly-L-lysine at a density of 12000 neurons/glass coverslip, and were cultured in phenol red free Neurobasal supplemented with B-27 and GlutaMAX I for 7 days.
Primary culture treatments
Cells were pre-treated for 12 h with fresh serum-free medium containing vehicle (0.1% DMSO) or 10 À 8 M DHEA. After pretreatments, cells were treated for 6 h with medium containing no glucose (glucose free DMEM) and vehicle (0.1% DMSO) or 10 À 8 M DHEA.
Immunocytochemistry in primary cultures
After treatments, cells were fixed for 20 min at room temperature in 4% paraformaldehyde and permeabilized for 15 min with 0.12% Triton-X plus 0.12% gelatin in PBS. Cells were then washed with PBS/gelatin and incubated for 1 h with anti-MAP2 chicken polyclonal antibody (ab5392, dilution 1:8000 in PBS/gelatine; Abcam, Cambridge, UK) and with anti-Tau rabbit polyclonal antibody (ab64193, dilution 1:500 in PBS/gelatine; Abcam, Cambridge, UK). After washing in the same buffer, cells were incubated for 30 min at room temperature with AlexaFluor546-conjugated goat anti-rabbit polyclonal (dilution 1:1000; Molecular Probes) and Alexa488 donkey anti-chicken (dilution 1:1000; Molecular Probes). Cell nuclei were stained with DAPI.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA). Data analysis was assessed by two-way ANOVA, considering DHEA treatment and glucose deprivation as factors, followed by Student-NewmanKeuls (SNK) post hoc test, and by one-way ANOVA, followed by Bonferroni post hoc test. Differences were considered statistically significant at p r0.05. Data are presented as mean 7 SEM and expressed as percentage of control values. Within each culture preparation, the assays were conducted in duplicate or triplicate. The N for statistical analysis was the number of independent experiments.
